Literature DB >> 14610170

Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.

Ekaterina A Korotkova1, Renee Park, Elena A Cherkasova, Galina Y Lipskaya, Konstantin M Chumakov, Esfir V Feldman, Olen M Kew, Vadim I Agol.   

Abstract

The global eradication of poliomyelitis will require substantial changes in immunization practices. One of the proposed scenarios includes cessation of vaccination with live oral poliovirus vaccine (OPV) and the creation of an OPV stockpile for emergency response in case of the reintroduction of poliovirus into circulation. We describe here a retrospective analysis of the cessation of OPV usage in a region of the Byelorussian Republic of the former Soviet Union in 1963 to 1966. During this period, a widespread circulation and evolution of independent lineages of vaccine-derived polioviruses took place in the region. Some of these lineages appeared to originate from OPV given to 40 children in the community during this period of essentially no vaccinations. The data demonstrate very high risks associated with both the local cessation of OPV vaccination and the proposed use of OPV to control a possible reemergence of poliovirus in the postvaccination period. The high transmissibility of OPV-derived viruses in nonimmune population, documented here, and the known existence of long-term OPV excretors should be also considered in assessing risks of the synchronized global cessation of OPV usage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610170      PMCID: PMC262597          DOI: 10.1128/jvi.77.23.12460-12465.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  Live bacterial delivery systems for development of mucosal vaccines.

Authors:  J E Thole; P J van Dalen; C E Havenith; P H Pouwels; J F Seegers; F D Tielen; M D van der Zee; N D Zegers; M Shaw
Journal:  Curr Opin Mol Ther       Date:  2000-02

2.  Circulation of a type 2 vaccine-derived poliovirus--Egypt, 1982-1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-01-26       Impact factor: 17.586

3.  Eradication of poliomyelitis.

Authors:  Akio Nomoto; Isao Arita
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

4.  Can a 'flawless' live vector vaccine strain be engineered?

Authors:  J E Galen; M M Levine
Journal:  Trends Microbiol       Date:  2001-08       Impact factor: 17.079

5.  Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication.

Authors:  P Más Lago; V M Cáceres; M A Galindo; H E Gary; M Valcarcel; J Barrios; L Sarmiento; I Avalos; J A Bravo; R Palomera; M Bello; R W Sutter; M A Pallansch; C A de Quadros
Journal:  Int J Epidemiol       Date:  2001-10       Impact factor: 7.196

6.  "Endgame" issues for the global polio eradication initiative.

Authors: 
Journal:  Clin Infect Dis       Date:  2001-11-19       Impact factor: 9.079

7.  Recombinant attenuated bacteria for the delivery of subunit vaccines.

Authors:  I Gentschev; G Dietrich; S Spreng; A Kolb-Mäurer; V Brinkmann; L Grode; J Hess; S H Kaufmann; W Goebel
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

8.  Natural genetic exchanges between vaccine and wild poliovirus strains in humans.

Authors:  S Guillot; V Caro; N Cuervo; E Korotkova; M Combiescu; A Persu; A Aubert-Combiescu; F Delpeyroux; R Crainic
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China.

Authors:  H M Liu; D P Zheng; L B Zhang; M S Oberste; M A Pallansch; O M Kew
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel.

Authors:  L M Shulman; Y Manor; R Handsher; F Delpeyroux; M J McDonough; T Halmut; I Silberstein; J Alfandari; J Quay; T Fisher; J Robinov; O M Kew; R Crainic; E Mendelson
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

View more
  28 in total

1.  Multiplex PCR method for identifying recombinant vaccine-related polioviruses.

Authors:  David R Kilpatrick; Karen Ching; Jane Iber; Ray Campagnoli; Christopher J Freeman; Nada Mishrik; Hong-Mei Liu; Mark A Pallansch; Olen M Kew
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

2.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Authors:  E A Cherkasova; M L Yakovenko; G V Rezapkin; E A Korotkova; O E Ivanova; T P Eremeeva; L I Krasnoproshina; N I Romanenkova; N R Rozaeva; L Sirota; V I Agol; K M Chumakov
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.

Authors:  Sebastian Zurbriggen; Kurt Tobler; Carlos Abril; Sabine Diedrich; Mathias Ackermann; Mark A Pallansch; Alfred Metzler
Journal:  Appl Environ Microbiol       Date:  2008-07-18       Impact factor: 4.792

6.  Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance.

Authors:  Maria L Yakovenko; Ekaterina A Korotkova; Olga E Ivanova; Tatyana P Eremeeva; Elena Samoilovich; Iryna Uhova; Gene V Gavrilin; Vadim I Agol
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

7.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

8.  Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence.

Authors:  Nidia De Jesus; David Franco; Aniko Paul; Eckard Wimmer; Jeronimo Cello
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 9.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

10.  Paralysis case and contact spread of recombinant vaccine-derived poliovirus, Spain.

Authors:  Ana Avellón; Maria Cabrerizo; Teresa de Miguel; Pilar Pérez-Breña; Antonio Tenorio; Jose Luis Pérez; Maria Victoria Martínez de Aragón; Gloria Trallero
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.